(from either a 4 or 6 mV LINAC) was used, with an 80-cm source to the axis distance. Circular secondary collimators ranged in diameter from 7.5 to 25 mm (mean 12.8 mm). The treatment dose was selected on the basis of tumor size, location, proximity of critical neurological structures, number of isocenters (tumors with complex geometric shapes were treated with multiple isocenters), and any history of conventional radiotherapy. The treatment dose ranged from 16 to 24 Gy (mean 20 Gy), which was prescribed to the 80% isodose contour at the edge of tumor (Table 2) .
In four patients the CyberKnife (Accuray, Inc., Sunnyvale, CA) was used. Patients were initially placed on the treatment couch, and a thermoplastic mask was created and attached to the couch. Patients were then transferred to a CT scanner (Lightspeed; General Electric, Milwaukee, WI), and 125 ml of Omnipaque contrast was administered. A series of CT scans was acquired at 1.25-mm slice thickness. The scans were then transferred to the treatment planning computer via a standard DICOM network. The tumor volume was outlined, and inverse treatment planning was then performed to achieve a highly conformal treatment plan, with attempts to minimize the dose to critical structures. The treatment dose to tumor periphery was 18 Gy in one patient, 22 Gy in two patients, and 24 Gy in the remaining patient.
Radiographic follow-up evaluation included 2-to 5-mm slice thickness Gd-enhanced MR images obtained every 4 months for the 1st year after treatment, every 6 months for the 2nd year, and annually thereafter. Clinical follow-up examination was conducted at the same intervals. The mean clinical and radiographic follow-up period was 44 months (range 8-77 months).
RESULTS

Neuroimaging-based Outcome
A decrease in tumor size was observed in six patients (75%) (Fig. 1) , the lesion disappeared in one (12.5%), and it progressed in one patient (12.5%). In the case in which MR imaging-based tumor disappearance was demonstrated 12 months posttreatment, recurrence was found after an additional 12 months and required another resection. This same patient was also noted to have metastases of his tentorial hemangiopericytoma to the temporalis muscle on the ipsilateral side (treated with resection). No other distant metastases were noted in this population. There was no radiological evidence of edema or necrosis in the tissue adjacent to the tumor in any patient in this series.
Clinical Outcome
Two patients (25%) in the series reported clinical improvement, both involving resolution or reduction in headaches, six patients (75%) indicated no change in symptoms, and no patient described a worsening of clinical status. Of the patients with cranial nerve deficits, none experienced any improvement in these deficits. The one patient in whom there was MR imaging evidence of tumor progression did not develop new clinical symptoms but continued to suffer baseline cranial nerve deficits. The patient with the hemangiopericytoma metastasis to the ipsilateral temporalis muscle noted the development of a mass under the temporal scalp, but experienced no neurological deficits.
The patient with documented tumor progression despite radiosurgery died during the follow-up period of complications related to a subsequent open surgery performed to excise the hemangiopericytoma. The overall 3-year survival rate was 88%.
DISCUSSION
Meningeal hemangiopericytomas often have clinical and radiographic presentations similar to meningiomas. 10, 12, 20 Hemangiopericytomas, however, are much more aggressive lesions, associated with high rates of local or distant recurrences, [1] [2] [3] 5, [10] [11] [12] 17, 18, 20, 23, 27, 31 and thus can behave similarly to other malignant lesions. 24 Resection is the initial treatment of choice, 26 but the highly vascular nature of the lesion and the location of some along the skull base results in mortality rates between 9 and 24%. 12, 14, 23, 25 Furthermore, the median time from resection to recurrence is 12 months, 8 and distant metastases have been noted to appear between a mean of 63 and 99 months after initial diagnosis. 7, 12, 14, 23, 25 Because of the recurrent nature of these lesions, exter-S. D. Chang and G. T. Sakamoto nal-beam radiotherapy has been used in the postoperative setting. Dube and Paulson 6 reported one of the first radiotherapy-based treatments of a hemangiopericytoma, noting a complete response. Mira, et al., 21 reported on a series of 11 patients in whom hemangiopericytomas were treated with more than 29 courses of radiotherapy, noting clinical response in 26 of the 29 courses, and complete regression following 14 courses. The authors of subsequent reports have also documented the benefit of radiotherapy in patients previously treated with surgery, even when a gross-total resection had been achieved. 5, [7] [8] [9] 12, 13, 15, 19, 32 Dufour, et al., 7 demonstrated that postoperative radiotherapy decreased the local recurrence rate to 12.5% after 50-to 64-Gy treatments compared with 88% after surgery alone. Guthrie, et al., 12 reported that radiotherapy after the first operation extended the mean time before first recurrence from 34 to 75 months and extended survival from 62 to 92 months. Glaholm, et al., 9 noted that even in those patients who had undergone resection previously, radiotherapy alone resulted in improved neurological performance in 38% of patients with inoperable hemangiopericytomas. Uemura, et al., 32 documented that radiotherapy even provided a benefit if delivered prior to resection, making the tumors less vascular and allowing resection with minimal blood loss.
Rationale for Radiosurgery
Based on the aforementioned data, as well as on their well-defined nature, hemangiopericytomas represent reasonable radiosurgical targets; some authors have even asserted that the highly vascular nature of these tumors likely increases their favorable response to treatment. 4 The primary challenge with resection alone is the a high rate of postoperative recurrence. Multiple resections are feasible, although not attractive because of the appreciable morbidity associated with multiple operations. In radiosurgery the efficacy of resection is combined with the more minimal rate of radiotherapy-induced morbidity.
Stereotactic radiosurgery should be particularly beneficial for skull base hemangiopericytomas, because these tumors usually present as reasonably small as a result of their proximity to cranial nerves, whose dysfunction often heralds the presence of tumor. Although conventional radiotherapy of skull base hemangiopericytomas may include critical skull base structures, such as the pituitary, optic nerves, and brainstem, the steep dose gradient that can be achieved using radiosurgery minimizes the radiation delivered to these areas. Consequently, it is possible to deliver a much larger, and presumably more efficacious, dose to the tumor without exceeding the radiation tolerance of normal tissues.
Previous Radiosurgical Reports
The first preliminary stereotactic radiosurgery report for hemangiopericytomas was reported by Coffey, et al. 4 A total of 11 hemangiopericytomas were treated in five patients, all of whom had undergone at least one prior craniotomy and three of whom had undergone prior radiotherapy to doses of 50 to 53 Gy. Marginal doses of 12 to 18 Gy were used, and the mean follow-up period was 14.8 months. Of the nine treated tumors for which radiographic follow-up data were available, eight decreased in size and one was no longer visible. Galanis, et al., 8 reported on 10 patients (five of whom were also included in the series by Coffey, et al.) in whom 20 hemangiopericytomas were treated with stereotactic radiosurgery (doses of 12-18 Gy). Seven of the 10 patients had previously undergone radiotherapy (dose range 3060-6400 cGy, median 5580 cGy). Fourteen of the hemangiopericytomas decreased in size, four disappeared radiographically, and two were stable in size.
Payne, et al., 22 analyzed data obtained in 12 patients with 15 stereotactic radiosurgery-treated intracranial hemangiopericytomas and reported follow-up data in 10 of these patients. All but one of the patients had undergone prior craniotomies (mean number of surgeries 2.9), and four patients had undergone prior fractionated radiotherapy. The mean peripheral dose was 14 Gy (range 2.8-25 Gy), and the mean clinical follow-up period was 24.8 months during which nine tumors decreased in size and three additional tumors were stable in size. Four of the nine tumors that decreased in size, however, subsequently
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Radiosurgery for hemangiopericytomas had increased in size after a mean of 22 months postradiosurgery.
In a recent report by Sheehan, et al., 26 the authors reviewed a series of 14 patients with 15 hemangiopericytomas treated with radiosurgery. Twenty-seven prior craniotomies had been conducted in this population, and seven patients had previously undergone radiotherapy (dose range 30-61 Gy, mean 47.3 Gy). The marginal radiosurgery doses ranged from 11 to 20 Gy, and the follow-up period ranged from 5 to 76 months (mean 31.3 months). On follow-up imaging, tumor regression was demonstrated in 12 of 15 lesions; three tumors were observed to have increased in size. Despite this 80% local control rate, 29% of the patients developed remote metastases, indicating that radiosurgery provided no protection from distant metastatic spread.
The Stanford Series
The findings in the present series confirm those of earlier reports. Tumor control was noted in 75% of the hemangiopericytomas treated during a mean 44 months follow-up period; this is comparable to the control rates documented in other series. 4, 8, 22, 26 Dose rates to tumor periphery in this series were slightly higher (mean 20.8 Gy) compared with those in other series (mean dose range 14-16 Gy). 4, 8, 22, 26 This higher mean dose, however, did not translate to increased tumor control rates or radiosurgeryrelated complication rates, perhaps due to the relatively small number of patients in all the reported series including the present one. As in the other series, all of our patients had previously undergone open resection, with some patients having undergone multiple excisions. In this population, further resection can be associated with increasing morbidity rates, a fact that makes radiosurgical treatment attractive.
Two additional observations confirm those made in other series. First, radiosurgery is a focal treatment and does not necessarily prevent regional and distant metastases. Metastases outside the treatment area were noted in this and other series, often developing within only a few years of treatment 4, 8, 22, 26 or even decades after initial treatment. 30 Second, the aggressive nature of hemangiopericytomas can result in initial decreases in tumor size or even disappearance, only to be followed by later regrowth. This was observed in the present study and also noted previously. 22 Both of these issues support the need for close clinical and radiographic follow-up observation in this patient population.
CONCLUSIONS
Resection remains the initial treatment for hemangiopericytomas, because histopathological diagnosis is required to distinguish them from meningiomas. Once resection is achieved, however, the high rates of hemangiopericytoma recurrence may be addressed by performing stereotactic radiosurgery, which has shown to provide significant benefit. Radiotherapy has been used to treat hemangiopericytomas, but their well-defined contrast-enhancing targets make them suitable for radiosurgery while minimizing dose to normal tissue. As suggested by this and previous reports, such hemangiopericytoma recurrences or remnants are readily, and very safely, treated radiosurgically, with increased tumor control rates. Because radiosurgery is a focal treatment, however, it does not eliminate the possibility of regional or distant metastases, which remain sources of significant morbidity and mortality in this patient population.
